Titlebook: Data Monitoring in Clinical Trials; A Case Studies Appro David L. DeMets,Curt D. Furberg,Lawrence M. Friedm Book 2006 Springer-Verlag New Y

脾氣暴躁的人

hermetic

Breaking New Ground: Data Monitoring in the Coronary Drug Projectmplex process. It may involve, among other things, the need to (1) determine whether the observed treatment differences are likely to represent real effects and are not due to chance; (2) weigh the importance of different response variables, some possibly trending in favor of the treatment and some

creatine-kinase

The Data Monitoring Experience in the Cardiac Arrhythmia Suppression Trial: The Need to Be Prepared s with a recent myocardial infarction would reduce the incidence of sudden death and total mortality, using three drugs known to suppress cardiac arrhythmias. Patients were randomized to receive either active drug or a matching placebo. The trial was terminated after only 15% of the planned-for even

松果

窩轉(zhuǎn)脊椎動物

largesse

Richard Lai,Ajin Jirachiefpattanaetic retinopathy. Benefit was detected early, but there where concerns about the possibility of late adverse effects. Calculations using projected blindness and death rates reassured the data monitoring committee that even large late adverse affects would not offset the early benefit already observed.

Tracheotomy

https://doi.org/10.1007/0-387-30107-0Division; Host; LDA; Statistica; complexity; design; eXist; evaluation; form; monitor; monitoring; object; repor

飛鏢

同義聯(lián)想法

GUILE

http://image.papertrans.cn/d/image/262983.jpg